General Information of Drug (ID: DMGJNQW)

Drug Name
WY-48989 Drug Info
Synonyms
WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; Wy-48989; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Terminated [1]
Cross-matching ID
PubChem CID
132006
CAS Number
CAS 136917-40-3
TTD Drug ID
DMGJNQW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Protease unspecific (PRO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prolastin DMYSCIL Alpha-1 antitrypsin deficiency 5C5A Approved [3]
ONO-3307 DMQGO74 Coagulation defect 3B10.0 Phase 2 [4]
SRD-441 DM5GAC4 Atopic dermatitis EA80 Phase 2 [5]
AZD-2551 DMZQEDY Chronic obstructive pulmonary disease CA22 Phase 1 [6]
AZD-3342 DMUCQPB Chronic obstructive pulmonary disease CA22 Discontinued in Phase 1 [7]
Aprosulate sodium DMRLHNW Coagulation defect 3B10.0 Discontinued in Phase 1 [8]
EP-2060 DMZA5Q4 Solid tumour/cancer 2A00-2F9Z Terminated [9]
CEP-431 DMDH0AM Alzheimer disease 8A20 Terminated [10]
ALP-242 DM592WE Cystic fibrosis CA25 Terminated [11]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protease unspecific (PRO) TTZBFA0 NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003820)
2 Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. Agents Actions. 1991 Sep;34(1-2):223-5.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854)
7 New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(227).
8 Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Pol J Pharmacol. 1996 May-Jun;48(3):317-22.
9 Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem. 2009 May;9(4):437-56.
10 US patent application no. 7,935,815, Imidazoyl pyridine compounds and salts thereof.
11 Oxidation resistant muteins of antileukoproteinase as potential therapeutic agents. Agents Actions Suppl. 1993;42:111-21.